Navigation Links
Neuromed Appoints Jeffrey Arcara and Gene Wright to Senior Management Team
Date:11/27/2007

CONSHOHOCKEN, PA and VANCOUVER, BC, Nov. 27 /PRNewswire/ - Neuromed Pharmaceuticals, a biopharmaceutical company developing new and improved chronic pain drugs, announced today that Jeffrey Arcara and Gene Wright have joined Neuromed as Vice President of Business Development and Vice President of Project Leadership, respectively. Both are newly created positions.

Mr. Arcara will be responsible for evaluating and negotiating in-licensing opportunities to complement our three pain programs including NMED-1077 (OROS(R) Hydromorphone) and our N- and T-type calcium channel blockers.

Dr. Wright will oversee project planning and will be involved in corporate strategic planning, development management processes and project management from conception through development cycle.

"Jeff's and Gene's direct experience with pain therapies, including opioids, will be immediately valuable to Neuromed as we advance our pivotal Phase 3 trials of NMED-1077 for the treatment of chronic pain," said Dr. Christopher Gallen, President & CEO. "Our ability to attract the caliber of seasoned executives such as Jeff and Gene is a testament to the enthusiasm around our programs and our potential to develop and market new and improved pain medicines. It is a pleasure to welcome them to our team."

About Jeffrey Arcara

Mr. Arcara was most recently an Executive Director of Marketing at Wyeth, where he was leading a commercial launch team for the investigational drug subcutaneous methylnaltrexone, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in patients receiving palliative care. Prior to Wyeth, Mr. Arcara was Vice President of Commercial Operations at InKine Pharmaceuticals. He has also held positions with Centocor and Abbott. Mr. Arcara received his M.B.A. in Marketing-Finance from the Anderson Graduate School of Management at UCLA and a B.A. in Marketing-Finance from the University of Wisconsin.

<
'/>"/>
SOURCE Neuromed Pharmaceuticals Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077
2. WorldHeart Appoints David Pellone Chief Financial Officer
3. Novo Nordisk Appoints New Leader of North American Business
4. The American Liver Foundation Appoints Rick Smith, a Twenty-Year Veteran of The MS Society, as Chief Executive Officer
5. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
6. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
7. Resonant Medical Appoints New Vice President of Global Sales
8. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
9. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
10. EPI-Q Opens East Coast Office and Appoints Vice President-Business Development
11. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... a five-year, $1.24 million Science Education Partnership Award ... to support NAHN’s collaborative project with the Hispanic ... Health Careers. , This collaborative NIH R25 program ... cultural and linguistic diversity among health professionals by ...
(Date:8/20/2014)... New Jersey (PRWEB) August 20, 2014 ... meeting the needs of an estimated tens of thousands ... of the new Bill A3525—a bill that would expand ... to grow their own cannabis—earlier this summer by State ... training for medicinal quality marijuana is growing. , To ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Verndale is ... Inc. 500|5000 list; an exclusive list ranking the fastest-growing ... are ranked according to their yearly percentage revenue growth ... 8th time on the Inc. 5000 list where it ... Company, Verndale offers its clients a wide range of ...
(Date:8/20/2014)... B. E. Smith, the only full-service ... been retained to lead a national chief operating ... in Hermiston, Ore. The top executive search firm ... recently placed more than 900 healthcare executives into organizations. ... progressive, not-for-profit healthcare organization serving a population of more ...
(Date:8/20/2014)... Biosimilars, which are similar versions of ... abbreviated process, could reap billions in health care ... Inc.’s (AIS) Specialty Pharmacy News offers coverage of ... and Drug Administration’s (FDA) recent acceptance of a ... Drugmaker Sandoz said July 24 that the FDA ...
Breaking Medicine News(10 mins):Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 3Health News:For the 8th Time, Verndale Has Been Honored on the Inc. 5000 List 2Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 2Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 3Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 2Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 3
... Company ... driving growth of EMR business, MARKHAM, ON, Feb. ... (TSX-V: NGH), one of North,America,s fastest growing healthcare software ... Helper business to Netsmart,Technologies Inc., a leading provider of ...
... a response in the adult brain , , FRIDAY, Feb. 29 ... ga-ga when they see a baby? , Scientists report ... up a specific region of the adult brain associated with ... looked at another adult face, suggesting there,s a neural basis ...
... BOTHELL, Wash., Feb. 29 Nastech,Pharmaceutical Company Inc. ... will,host a conference call with investors and security ... Eastern time (8:30 a.m. Pacific time) to,discuss the ... in the live conference call, U.S. residents should,dial ...
... quantify heritability of the disease , , FRIDAY, Feb. 29 (HealthDay ... chronic bronchitis, genes also play a major role in the ... which analyzed data on more than 40,000 twins born in ... percent of the risk for chronic bronchitis and that 14 ...
... published in the February issue of Injury Prevention estimates ... schools in 2005-2007 were directly related to an action ... or disciplinary committee. , Researchers in the Center for ... analyzed data from the 2005-2006 and 2006-2007 National High ...
... under 60 survived longer than people who had single ... double lung transplant leads to longer survival than a ... are in the final stages of chronic obstructive pulmonary ... lung transplants are both recognized as treatment options for ...
Cached Medicine News:Health News:Nightingale announces US$12.3 million sale of its Therapist Helper business 2Health News:Nightingale announces US$12.3 million sale of its Therapist Helper business 3Health News:Nightingale announces US$12.3 million sale of its Therapist Helper business 4Health News:Babies Really Can Light Up Your Life 2Health News:Babies Really Can Light Up Your Life 3Health News:Nastech Pharmaceutical Company Inc. to Hold Conference Call to Discuss Corporate Restructuring and Future Strategy on Monday, March 3, 2008 2Health News:Genetic Factors for Smoking Boost Chronic Bronchitis Risk 2Health News:When the rules of the game are broken: Research studies sports injuries related to illegal activity 2Health News:Double Lung Transplant Better for Younger COPD Patients 2
(Date:8/19/2014)... MENLO PARK, Calif. , Aug. 19, 2014 ... company") announced today a protocol amendment to allow for expanded ... the U.S. Food and Drug Administration (FDA) and that a ... opened at three clinical trial sites in the ... proceeds of US$2.9 million have been raised through warrant exercise ...
(Date:8/19/2014)... 19, 2014 ,Weight Loss- Market ... 2014, report provides comprehensive insights about phase III pipeline ... objective of the report is to establish the understanding ... drugs across the different countries and regions. While the ... report also provides details on the drug master filings ...
(Date:8/18/2014)... and HERZLIYA-PITUACH, Israel , Aug. 19, 2014 ... North Premier, Stockholm : "IMNP"), a biotechnology ... application to list its common stock on the NASDAQ Capital ... unit of the NASDAQ OMX Group. IMMUNE,s common stock is ... the opening of trading on August 21, 2014 under the ...
Breaking Medicine Technology:DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 4DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 5DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 6DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 7Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 4Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 2Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 3Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 4
... Dec. 27, 2011 Neuralstem, Inc. (NYSE Amex: ... Food and Drug Administration to advance to Phase Ib in ... NSI-189, for the treatment of major depressive disorder ... the drug in depressed patients. NSI-189 is a proprietary new ...
... Dec. 27, 2011 /PRNewswire-Asia/ -- China Botanic Pharmaceutical ... Botanic" or the "Company"), a developer, manufacturer and ... Medicines ("TCM") in China, today announced that the ... 66th PHARMCHINA fair ("the Fair") recently held in ...
Cached Medicine Technology:Neuralstem's NSI-189 Trial in Major Depressive Disorder Receives FDA Approval to Advance to Phase Ib 2Neuralstem's NSI-189 Trial in Major Depressive Disorder Receives FDA Approval to Advance to Phase Ib 3Neuralstem's NSI-189 Trial in Major Depressive Disorder Receives FDA Approval to Advance to Phase Ib 4China Botanic Exhibits All-Natural Anti-depressant Products at the 66th PHARMCHINA Fair 2China Botanic Exhibits All-Natural Anti-depressant Products at the 66th PHARMCHINA Fair 3
The Redi-glaze spectacle magnifier is an aspheric lens, glazed into a standard Keeler LVA frame....
This set is designed to introduce the low vision practitioner to the Keeler telescopic system....
... Featuring up to 20 ... examination in the vertical, ... plus the option to ... corneal transillumination., ,Filters include ...
Comes complete in its own carrying case. There are 24 lenses, 13mm diameter -6D to +6D in 0.5D steps. Mounted in tough, yet light alloy frame....
Medicine Products: